Why the study?
Patients with chronic kidney disease are at high risk of type 4 cardiorenal-anemia syndrome, which worsens kidney and heart function and increases mortality, and the efficacy and safety of roxadustat in treating type 4 CRAS are unknown.
Does roxadustat improve heart function compared to erythropoietin in patients with type 4 cardiorenal-anemia syndrome?
Population
68 patients diagnosed with type 4 cardiorenal-anemia syndrome
Comparison
Roxadustat vs erythropoietin
Design
Randomized open-label controlled trial
Follow-up
24 weeks
Key result
Roxadustat will be evaluated against erythropoietin for its ability to improve heart function in 68 patients with type 4 cardiorenal-anemia syndrome in this planned randomized controlled trial.
Authors
Loading...
Planned RCT addresses evidence gap in type 4 cardiorenal-anemia syndrome; leaves open whether roxadustat improves heart function over erythropoietin.
RCT (n=68)
Open-label
Computer-generated sequence (1:1 ratio)
No
Does roxadustat improve heart function compared to erythropoietin in patients with type 4 cardiorenal-anemia syndrome?
This study protocol outlines a randomized trial to evaluate the efficacy and safety of roxadustat compared to erythropoietin for improving heart function in patients with type 4 cardiorenal-anemia syndrome.
Xu et al. (2022) conducted an RCT in Type 4 Cardiorenal-Anemia Syndrome (n=68). Roxadustat vs. Erythropoietin was evaluated on Change in brain natriuretic peptide (BNP), 6-min walk test (6-WT), and left ventricular ejection fraction (LVEF) from baseline to 24 weeks. Roxadustat will be evaluated against erythropoietin for its ability to improve heart function in 68 patients with type 4 cardiorenal-anemia syndrome in this planned randomized controlled trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: